The findings in this case indicate that atorvastatin, like other DL-3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, may increase the risk of myositis and rhabdomyolysis when used in combination with gemfibrozil.
|Original language||English (US)|
|Number of pages||2|
|Journal||American Journal of Cardiology|
|State||Published - Feb 1 1998|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine